Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT01135056
• Date of registration: 24/05/2010
• Prospective Registration: Yes
• Primary sponsor: Singapore General Hospital
• Public title: Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) SIRveNIB
• Scientific title: Phase III Multi-Centre Open-Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)
• Date of first enrolment: July 2010
• Target sample size: 360
• Recruitment status: Unknown status
• URL: https://clinicaltrials.gov/show/NCT01135056
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 3

Countries of recruitment

Australia, Brunei Darussalam, China, Hong Kong, Indonesia, Korea, Republic of, Malaysia, Mongolia, Myanmar, New Zealand, Philippines, Singapore, Taiwan, Thailand, Vietnam

Contacts

• Name: Pierce KH Chow, MBBS, PhD
• Affiliation: National Cancer Centre, Singapore

Key inclusion & exclusion criteria

Inclusion Criteria:

- Disease must be locally advanced as defined by BCLC (B) intermediate stage or BCLC (C)
advanced stage without extra-hepatic disease (only with branch portal vein
thrombosis).

- Willing, able and mentally competent to provide written informed consent prior to any
testing undertaken for this study protocol, including screening tests and evaluations
that are not considered to be part of the subject's routine care.

- Aged 18 years/older (either gender).

- Unequivocal diagnosis of HCC.

- HCC not amenable to surgical resection or immediate liver transplantation, or cannot
be optimally treated with local ablative techniques such as RFA, consistent with the
practice of the clinical trial centre.

- Measurable disease, defined as at least one lesion that can be accurately measured in
at least one dimension (longest diameter to be recorded) as = 10 mm with spiral CT
scan or MRI.

- ECOG performance status 0-1.

- Child-Pugh A-B (up to 7 points)

- Adequate haematological, renal and hepatic function as follows:

- Leukocytes = 2,500/µL

- Platelets = 80,000/µL

- Haemoglobin > 9.5g/dL

- Total bilirubin < 2.0mg/dL

- INR = 2.0

- ALP = 5 x institutional ULN

- AST and ALT = 5 x institutional ULN

- Albumin = 2.5g/dL

- Creatinine = 2.0mg/dL

- Life expectancy of at least 3 months without any active treatment.

- Suitable for protocol treatment as determined by clinical assessment undertaken by the
Investigator.

- Female patients must be either postmenopausal or, if premenopausal, must have a
negative pregnancy test and agree to use 2 forms of contraception if sexually active
during their study participation.

- Male patients must be surgically sterile, or if sexually active and having a
pre-menopausal female partner then must be using an acceptable form of contraception.

Exclusion Criteria:

- Have had more than 2 administrations of hepatic artery directed therapy.

- Subjects who have had hepatic artery directed therapy done < 4 weeks prior to study
entry.

- Have had systemic chemotherapy for HCC except for prior adjuvant or neoadjuvant
therapy given more than 6 months from enrolment.

- have had prior treatment with Sorafenib or VEGF inhibitors.

- Prior hepatic radiation therapy for HCC or other malignancy.

- Currently receiving any other investigational agents for the treatment of their
cancer.

- Has intractable clinical ascites (in spite of optimal diuretic treatment) or any other
clinical signs of liver failure, on physical examination.

- Complete main portal vein thrombosis.

- Any metastatic disease (local-regional lymph nodes measuring less than 2 cm in
greatest diameter or lung nodules measuring less than 1 cm are not contraindications
as per Investigator discretion).

- Any other concurrent malignancy, except for adequately treated basal cell or squamous
cell skin cancer, in situ cervical cancer, or other cancer for which the patient has
been disease-free for at least 5 years.

- Presence of clinical signs of CNS metastases due to their poor prognosis and because
progressive neurologic dysfunction would confound the evaluation of neurologic and
other adverse events.

- Uncontrolled inter-current illness including, but not limited to, ongoing or active
infection (except viral hepatitis), symptomatic congestive heart failure, unstable
angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
would limit compliance with study requirements.

- Any of the following contraindications to angiography and selective visceral
catheterization:

- Bleeding diathesis, not correctable by the standard forms of therapy.

- Severe peripheral vascular disease that would preclude arterial catheterization.

- Portal hypertension with hepato-fugal flow as documented on baseline spiral CT scan.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to SIR-Spheres or Sorafenib.

- Inability or unwillingness to understand or sign a written informed consent document.

- Female subjects who are pregnant or currently breastfeeding.

- Female subjects, unless postmenopausal or surgically sterile, unwillingness to
practice effective contraception, as per Investigator discretion during the study. The
rhythm method is not to be used as the sole method of contraception.

- Male subjects, unwillingness to practice effective contraception (per Investigator
discretion) while taking part in this study, because the effect of the SIR-Spheres
treatment on sperm or upon the development of an unborn child are unknown.

- Current enrolment in any other investigational therapeutic drug or device study.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Hepatocellular Carcinoma

Intervention(s)

Drug: Sorafenib tosylate

Device: SIR-Spheres

Primary Outcome(s)

Overall Survival [Time Frame: 2 years]

Secondary Outcome(s)

Progression free survival in the liver [Time Frame: 2 years]

Tumour Response Rate [Time Frame: 2 years]

Progression free survival overall [Time Frame: 2 years]

Liver Transplantation Rate [Time Frame: Up to 2 years]

Toxicity and Safety [Time Frame: Up to 2 years]

Disease control rate [Time Frame: 2 years]

Health Related Quality of Life (QoL) [Time Frame: Up to 2 years]

Liver resection rate [Time Frame: Up to 2 years]

Time to Disease Progression [Time Frame: Up to 2 years]

Secondary ID(s)

AHCC06

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Secondary Sponsor(s)

National Cancer Centre, Singapore

Sirtex Medical

Singapore Clinical Research Institute

National Medical Research Council (NMRC), Singapore